regorafenib + mFOLFOX6

**Regorafenib + mFOLFOX6** is a combination regimen of the multikinase inhibitor regorafenib with the chemotherapy regimen mFOLFOX6, used primarily for metastatic colorectal cancer (CRC). - **Regorafenib** is a small molecule inhibitor targeting multiple protein kinases related to angiogenesis (including VEGFR1-3, TIE2), oncogenesis (such as KIT, RET, RAF-1, BRAF), and the tumor microenvironment (PDGFR, FGFR). - **mFOLFOX6** (modified FOLFOX6) is a chemotherapy regimen consisting of oxaliplatin, leucovorin (folinic acid), and fluorouracil. - The combination is under investigation as a first-line and later-line treatment in CRC. - Regorafenib inhibits tumor angiogenesis and oncogenic kinases, while mFOLFOX6 acts primarily via DNA damage (oxaliplatin) and inhibition of thymidylate synthase (5-FU), impeding DNA synthesis. - Clinical studies suggest the combination increases disease control and survival over regorafenib monotherapy, with manageable toxicity but without significant improvement in response rate over chemotherapy alone[1][3]. - Regorafenib (by Bayer) is approved for previously treated metastatic CRC; mFOLFOX6 is standard for CRC. Regorafenib + mFOLFOX6 is not an approved fixed combination product but is under clinical study[3][5].